PDF(Pubmed)
Abstract：
Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy. Objective: a meta-analysis was conducted to evaluate the potential efficacy of resveratrol in treating nonalcoholic fatty liver disease by analyzing both preclinical studies and clinical trials. Method: PubMed, Embase and Web of Science were searched for the included literature with the criteria for screening. Quantitative synthesis and meta-analyses were performed by STATA 16.0. Results: Twenty-seven studies were included, and the results indicated that resveratrol effectively improved liver function, reduced fatty liver indicators, and affected other indices in preclinical studies. The effective dosage ranged from 50 mg/kg-200 mg/kg, administered over a period of 4-8 weeks. While there were inconsistencies between clinical trials and preclinical research, both study types revealed that resveratrol significantly reduced tumor necrosis factor-α levels, further supporting its protective effect against nonalcoholic fatty liver disease. Additionally, resveratrol alleviated nonalcoholic fatty liver disease primarily via AMPK/Sirt1 and anti-inflammatory signaling pathways. Conclusion: Current meta-analysis could not consistently verify the efficacy of resveratrol in treating nonalcoholic fatty liver disease, but demonstrated the liver-protective effects on nonalcoholic fatty liver disease. The large-sample scale and single region RCTs were further needed to investigate the efficacy.
摘要：
背景：白藜芦醇，在各种植物中发现的多酚，以其多种生物活性而闻名，并已与非酒精性脂肪性肝病（NAFLD）有关。然而,没有关于其疗效的高质量证据.目的：通过分析临床前研究和临床试验，评价白藜芦醇治疗非酒精性脂肪肝的潜在疗效。方法:PubMed,在Embase和WebofScience中搜索了包含筛选标准的文献。STATA16.0进行了定量合成和荟萃分析。结果：共纳入27项研究，结果表明白藜芦醇能有效改善肝功能,脂肪肝指标减少，并影响临床前研究中的其他指标。有效剂量范围为50mg/kg-200mg/kg，在4-8周的时间内给药。虽然临床试验和临床前研究之间存在不一致，两种研究类型都显示白藜芦醇显著降低肿瘤坏死因子-α水平，进一步支持其对非酒精性脂肪性肝病的保护作用。此外,白藜芦醇主要通过AMPK/Sirt1和抗炎信号通路缓解非酒精性脂肪性肝病。结论：目前的荟萃分析不能一致验证白藜芦醇治疗非酒精性脂肪肝的疗效。但证明了对非酒精性脂肪性肝病的肝脏保护作用。进一步需要大样本尺度和单区域RCT来研究疗效。
